ResMed (RMD) PT Raised to $302 at KeyBanc

KeyBanc analyst Brett Fishbin raised the price target on ResMed (NYSE: RMD) to $302.00 (from $299.00) while maintaining an Overweight rating.

The analyst commented: "Maintain OW and raise PT to $302 post 2Q on higher ests. We view RMD's 2Q26 release as largely positive and supportive of our overall thesis, given a solid revenue beat and continued upside to gross margins. More specifically: 1) 1Q26 revenue was ahead of expectations with Masks & Accessories and Devices driving outperformance, while SAAS represented a modest offset; 2) we were encouraged by an upward revision to the low end of its gross margin guidance; and 3) we anticipate continued flexibility in capital allocation given its strong financial position exiting 2Q26."

You May Also Be Interested In

• Correction: Kepler Cheuvreux Upgrades Siemens AG (SIE:GR) (SIEGY) to Hold
• BNP Paribas Exane Upgrades Novonesis A/S (NSISB:DC) to Neutral
• Freedom Broker Starts Unity Bancorp (UNTY) at Hold